Avacta Group Plc
AVCTF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$413.77M
Close$
$-0.02
101.9% downside
Current Fair Value
101.9% downsideOvervalued by 101.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $413.77 Million |
|---|---|
| Enterprise Value | $413.36 Million |
| Earnings per Share | $-0.1 |
| Beta | -0.1 |
| Outstanding Shares | 449,438,000 |
Return
| Return on Equity | -1888.74% |
|---|---|
| Return on Assets | -230.07% |
| Return on Invested Capital | -1593.80% |
Valuation & Multiples
| P/E Ratio | -6.63 |
|---|---|
| PEG | -84.19 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 36.16 |
| Enterprise Value to EBIT | -6.86 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 5.27 |
Revenue Sources
No data
Next Earnings Call
Expected Date
April 22, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Avacta Group Plc
154 employees
CEO: Christina Marie Coughlin
Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, levera...